Indication

In combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2460
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
10 October 2022
SMC meeting date:
06 September 2022
Patient group submission deadline:
06 June 2022